FAQ

Picoplatin

Known as: Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3), Cis-Amminedichloro (2-Methylpyridine) Platinum, Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)- 
A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2018
02420072018

Related topics

Related topics

3 relations

Narrower (2)

AMD 473ZD 0473
JM-473

Related mentions per year

Related mentions per year

1991-2018
1990200020102020
Picoplatin
ZD 0473
AMD 473
JM-473

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Exploring the interaction between picoplatin and human serum albumin: The effects on protein structure and activity.
For the first time, the effects of picoplatin on the structure and esterase-like catalytic activity of human serum albumin (HSA… (More)
Is this relevant?
Review
2013
Review
2013
Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer.
INTRODUCTION Picoplatin was developed as platinum coordination complex to overcome development of resistance, through conjugation… (More)
Is this relevant?
2012
2012
DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.
Oxaliplatin, satraplatin, and picoplatin are cisplatin analogs that interact with DNA forming intrastrand and interstrand DNA… (More)
Is this relevant?
2012
2012
Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.
Picoplatin is a sterically hindered mononuclear platinum drug undergoing clinical trials. The 2-methylpyridine ring provides… (More)
Is this relevant?
2010
2010
Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.
Picoplatin, a third-generation platinum agent, is efficacious against lung cancers that are otherwise resistant or become… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The status of platinum anticancer drugs in the clinic and in clinical trials.
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
Picoplatin is a new generation platinum designed to overcome platinum resistance. The goal of this study was to assess picoplatin… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
2010
2010
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds
PURPOSE Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase (PDK), and thus promotes glucose oxidation over glycolysis… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2009
2009
Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
PURPOSE This study was designed to confirm the efficacy and safety of picoplatin, a cisplatin analog designed to overcome… (More)
Is this relevant?
Review
2007
Review
2007
Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
The three platinum-containing drugs that have been thus far approved by the FDA - cisplatin, carboplatin and oxaliplatin - have… (More)
Is this relevant?